RNTX NASDAQ
Rein Therapeutics Inc.
1W: +7.0%
1M: +3.3%
3M: -22.3%
YTD: -35.9%
1Y: -32.1%
$0.80
-0.05 (-6.03%)
Weekly Expected Move ±12.1%
$1
$1
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
25 relationships25
As Filer
counterparties named
0
As Counterparty
mentioned by others
5
Rel. Types
2021-03-31
Earliest Filing
2026-01-16
Latest Filing
partner: 15
investor: 5
customer: 2
supplier: 2
target: 1
Counterparties (Filed by RNTX)
25 relationshipsCompanies named in RNTX's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Funicular Funds, LP | — | investor | Issued and sold an unsecured promissory note in a private placement. | 2026-01-16 | View |
| Bios Equity Partners, LP | — | investor | Entity affiliated with Bios Partners that exchanged 2023 Warrants for Pre-Funded Warrants and made cash payments. | 2025-04-22 | View |
| Bios Purchaser | — | investor | Entity affiliated with Bios Partners that purchased additional Pre-Funded Warrants in a private placement. | 2025-04-22 | View |
| William Blair & Company, L.L.C. | — | customer | Previous sales agent whose agreement was terminated. | 2024-07-26 | View |
| JonesTrading Institutional Services LLC | — | customer | Previous sales agent whose agreement was terminated. | 2024-07-26 | View |
| Titan Partners Group LLC | KMCM | partner | Underwriter for the offering of common stock and warrants | 2024-05-01 | View |
| American Capital Partners, LLC | AIG | partner | Parent company of Titan Partners Group LLC | 2024-05-01 | View |
| Bios Partners | — | investor | Lead investor in the private placement financing and majority shareholder of Lung prior to the merger. | 2023-10-31 | View |
| Nantahala Capital | — | investor | Investor participating in the private placement financing. | 2023-10-31 | View |
| Mirum Pharmaceuticals | MIRM | partner | Company on whose board of directors William C. Fairey serves. | 2023-10-31 | View |
| Ascendis Pharma A/S | ASND | partner | Company on whose board of directors William C. Fairey serves. | 2023-10-31 | View |
| MyoKardia, Inc. | — | partner | Company where William C. Fairey previously served as Executive Vice President and Chief Commercial Officer. | 2023-10-31 | View |
| Bristol Myers Squibb | CELG-RI | partner | Company that acquired MyoKardia, Inc. | 2023-10-31 | View |
| ChemoCentryx, Inc. | CCXI | partner | Company where William C. Fairey previously served as Executive Vice President and Chief Operating Officer. | 2023-10-31 | View |
| Actelion Pharmaceuticals Ltd. | — | partner | Company where William C. Fairey previously served in various roles. | 2023-10-31 | View |
| Lung Therapeutics, Inc. | — | target | Target company acquired by Aileron Therapeutics, Inc. in a merger transaction. | 2023-10-31 | View |
| ReViral Ltd. | — | partner | Company where Alan A. Musso previously served as Chief Financial Officer. | 2023-10-31 | View |
| Pfizer Inc. | PFE | partner | Company that acquired ReViral Ltd. | 2023-10-31 | View |
| Peloton Therapeutics Inc. | — | partner | Company where Alan A. Musso previously served as Chief Financial Officer and Treasurer. | 2023-10-31 | View |
| Merck & Co. | MRK | partner | Company that acquired Peloton Therapeutics Inc. | 2023-10-31 | View |
| Bellicum Pharmaceuticals, Inc. | — | partner | Company where Alan A. Musso previously served as Chief Financial Officer and Treasurer. | 2023-10-31 | View |
| Targacept, Inc. | — | partner | Company where Alan A. Musso previously served in various positions. | 2023-10-31 | View |
| Johnson & Johnson | JNJ | partner | Company that acquired Actelion Pharmaceuticals Ltd. | 2023-10-31 | View |
| Vittoria Industries North America, Inc. | — | supplier | Sublessor in a sublease agreement for office space | 2021-03-31 | View |
| Waterfront Equity Partners, LLC | — | supplier | Lessor in a sublease agreement for office space | 2021-03-31 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-04 | Regulation FD; Exhibits | View | |
| 2026-08-27 | Delisting Notice | View | |
| 2026-07-21 | Shareholder Vote | View | |
| 2026-05-04 | Material Agreement; Other Events; Exhibits | Agreement | View |
| 2026-03-02 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Unregistered Sale | Agreement | View |
| 2026-02-19 | Departure/Election of Directors; Appointment of Officers | View | |
| 2026-01-16 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Unregistered Sale | Agreement | View |
| 2025-12-11 | Termination of Material Definitive Agreement | View | |
| 2025-11-03 | Other Events; Financial Statements and Exhibits | View | |
| 2025-10-24 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Unregistered Sale | Agreement | View |
| 2025-10-09 | Other Events; Financial Statements and Exhibits | View | |
| 2025-09-22 | Other Events | View | |
| 2025-09-09 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Unregistered Sale | Agreement | View |
| 2025-08-19 | Other Events; Financial Statements and Exhibits | View | |
| 2025-07-30 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Unregistered Sale | Agreement | View |
| 2025-07-23 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-07-11 | Amendments to Articles of Incorporation or Bylaws; Other Events; Financial Statements and Exhibits | View | |
| 2025-06-24 | Other Events | View | |
| 2025-06-12 | Other Events | View | |
| 2025-05-15 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR